480 PLEASANT STREET, WATERTOWN, MA
Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Investor Presentation
EyePoint, Inc. Files Complaint Against Ocular Therapeutix for Defamation
Financial Results, Press Release
Reports Corporate Update and Anticipated Pivotal Milestones for 2026
EyePoint Pharmaceuticals Changes Name to EyePoint, Inc. Effective December 8,...
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus
Submission Upload